Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial (Q24564715)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial	scientific article

Statements

scholarly article

0 references

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial (English)

0 references

phase II clinical trial

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

Tomas Olsson

1

0 references

Aaron Boster

2

0 references

Óscar Fernández

3

0 references

Mark S Freedman

4

0 references

Carlo Pozzilli

5

0 references

Doris Bach

6

0 references

Ouali Berkani

7

0 references

Markus S Mueller

8

0 references

Tatiana Sidorenko

9

0 references

Ernst-Wilhelm Radue

10

0 references

Maria Melanson

11

0 references

language of work or name

0 references

publication date

November 2014

0 references

Journal of Neurology, Neurosurgery and Psychiatry

0 references

85

0 references

11

0 references

1198-208

0 references

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

Multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

24 March 2017

Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Sphingosine-1-phosphate receptor signalling in the heart

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

The prevalence of multiple sclerosis in the world: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

27 September 2017

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

30 May 2018

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2013-307282

21 January 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215282

28 November 2018

Combining multiple comparisons and modeling techniques in dose-response studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24659797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JNNP-2013-307282

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24564715&oldid=1574075316"